Review



stata software version 9 4  (STATA Corporation)


Bioz Verified Symbol STATA Corporation is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    STATA Corporation stata software version 9 4
    Stata Software Version 9 4, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 12510 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stata+software+version+9+4/pmc12935162-160-5-9?v=STATA+Corporation
    Average 99 stars, based on 12510 article reviews
    stata software version 9 4 - by Bioz Stars, 2026-08
    99/100 stars

    Images



    Similar Products

    stata software version 9 4  (STATA Corporation)
    99
    STATA Corporation stata software version 9 4
    Stata Software Version 9 4, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stata+software+version+9+4/pmc12935162-160-5-9?v=STATA+Corporation
    Average 99 stars, based on 1 article reviews
    stata software version 9 4 - by Bioz Stars, 2026-08
    99/100 stars
    		  Buy from Supplier
    statistical software version 9 4  (STATA Corporation)
    99
    STATA Corporation statistical software version 9 4
    Statistical Software Version 9 4, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stata+software+version+9+4/pmc10926326-97-7-6?v=STATA+Corporation
    Average 99 stars, based on 1 article reviews
    statistical software version 9 4 - by Bioz Stars, 2026-08
    99/100 stars
    		  Buy from Supplier
    ts1m7 version 9 4 statistical software  (STATA Corporation)
    99
    STATA Corporation ts1m7 version 9 4 statistical software
    Ts1m7 Version 9 4 Statistical Software, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stata+software+version+9+4/pmc10714239__mmc4-74-7-37?v=STATA+Corporation
    Average 99 stars, based on 1 article reviews
    ts1m7 version 9 4 statistical software - by Bioz Stars, 2026-08
    99/100 stars
    		  Buy from Supplier
    joinpoint software version 4 9 0 0  (STATA Corporation)
    99
    STATA Corporation joinpoint software version 4 9 0 0
    Trends in percentage of patients aged 55-80 and aged 45-54, 55-64, and 65-80 in National Cancer Database with stage I non-small cell lung cancer at diagnosis from 2010 to 2018. Each consecutive annual interval is represented as a point value. Vertical dotted line represents date when United States Preventive Services Task Force (USPSTF) first recommended low dose computed tomography (LDCT) lung cancer screening. Annual percentage changes: 55-80 (2010-13): 1.9%, P=0.06; 55-80 (2013-18): 3.9%, P<0.001; 45-54 (2010-18): 3.4%, P<0.001; 55-64 (2010-13): 1.3%, P=0.30; 55-64 (2013-18): 4.9%, P=0.001; 65-80 (2010-14): 2.3%, P=0.001; 65-80 (2014-18): 3.8%, P<0.001. “Raw” denotes actual percentage of patients with stage I disease at diagnosis each year. “Model” denotes results of <t>joinpoint</t> regression modeling. An interactive version of this graphic is available at https://public.flourish.studio/visualisation/8864567/
    Joinpoint Software Version 4 9 0 0, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stata+software+version+9+4/pmc08965744-148-2-7?v=STATA+Corporation
    Average 99 stars, based on 1 article reviews
    joinpoint software version 4 9 0 0 - by Bioz Stars, 2026-08
    99/100 stars
    		  Buy from Supplier
    statistical analysis software sas 9 4 version  (STATA Corporation)
    99
    STATA Corporation statistical analysis software sas 9 4 version
    Trends in percentage of patients aged 55-80 and aged 45-54, 55-64, and 65-80 in National Cancer Database with stage I non-small cell lung cancer at diagnosis from 2010 to 2018. Each consecutive annual interval is represented as a point value. Vertical dotted line represents date when United States Preventive Services Task Force (USPSTF) first recommended low dose computed tomography (LDCT) lung cancer screening. Annual percentage changes: 55-80 (2010-13): 1.9%, P=0.06; 55-80 (2013-18): 3.9%, P<0.001; 45-54 (2010-18): 3.4%, P<0.001; 55-64 (2010-13): 1.3%, P=0.30; 55-64 (2013-18): 4.9%, P=0.001; 65-80 (2010-14): 2.3%, P=0.001; 65-80 (2014-18): 3.8%, P<0.001. “Raw” denotes actual percentage of patients with stage I disease at diagnosis each year. “Model” denotes results of <t>joinpoint</t> regression modeling. An interactive version of this graphic is available at https://public.flourish.studio/visualisation/8864567/
    Statistical Analysis Software Sas 9 4 Version, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stata+software+version+9+4/pm32835523-69-4-13?v=STATA+Corporation
    Average 99 stars, based on 1 article reviews
    statistical analysis software sas 9 4 version - by Bioz Stars, 2026-08
    99/100 stars
    		  Buy from Supplier
    statistical software sas software version 9 4  (STATA Corporation)
    99
    STATA Corporation statistical software sas software version 9 4
    Trends in percentage of patients aged 55-80 and aged 45-54, 55-64, and 65-80 in National Cancer Database with stage I non-small cell lung cancer at diagnosis from 2010 to 2018. Each consecutive annual interval is represented as a point value. Vertical dotted line represents date when United States Preventive Services Task Force (USPSTF) first recommended low dose computed tomography (LDCT) lung cancer screening. Annual percentage changes: 55-80 (2010-13): 1.9%, P=0.06; 55-80 (2013-18): 3.9%, P<0.001; 45-54 (2010-18): 3.4%, P<0.001; 55-64 (2010-13): 1.3%, P=0.30; 55-64 (2013-18): 4.9%, P=0.001; 65-80 (2010-14): 2.3%, P=0.001; 65-80 (2014-18): 3.8%, P<0.001. “Raw” denotes actual percentage of patients with stage I disease at diagnosis each year. “Model” denotes results of <t>joinpoint</t> regression modeling. An interactive version of this graphic is available at https://public.flourish.studio/visualisation/8864567/
    Statistical Software Sas Software Version 9 4, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stata+software+version+9+4/pmc08077040__jamaneurol___e210659___s001-1721-0-9?v=STATA+Corporation
    Average 99 stars, based on 1 article reviews
    statistical software sas software version 9 4 - by Bioz Stars, 2026-08
    99/100 stars
    		  Buy from Supplier
    sas stata version 9 4 software  (STATA Corporation)
    99
    STATA Corporation sas stata version 9 4 software
    Trends in percentage of patients aged 55-80 and aged 45-54, 55-64, and 65-80 in National Cancer Database with stage I non-small cell lung cancer at diagnosis from 2010 to 2018. Each consecutive annual interval is represented as a point value. Vertical dotted line represents date when United States Preventive Services Task Force (USPSTF) first recommended low dose computed tomography (LDCT) lung cancer screening. Annual percentage changes: 55-80 (2010-13): 1.9%, P=0.06; 55-80 (2013-18): 3.9%, P<0.001; 45-54 (2010-18): 3.4%, P<0.001; 55-64 (2010-13): 1.3%, P=0.30; 55-64 (2013-18): 4.9%, P=0.001; 65-80 (2010-14): 2.3%, P=0.001; 65-80 (2014-18): 3.8%, P<0.001. “Raw” denotes actual percentage of patients with stage I disease at diagnosis each year. “Model” denotes results of <t>joinpoint</t> regression modeling. An interactive version of this graphic is available at https://public.flourish.studio/visualisation/8864567/
    Sas Stata Version 9 4 Software, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stata+software+version+9+4/pm30049642-60-16-16?v=STATA+Corporation
    Average 99 stars, based on 1 article reviews
    sas stata version 9 4 software - by Bioz Stars, 2026-08
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Trends in percentage of patients aged 55-80 and aged 45-54, 55-64, and 65-80 in National Cancer Database with stage I non-small cell lung cancer at diagnosis from 2010 to 2018. Each consecutive annual interval is represented as a point value. Vertical dotted line represents date when United States Preventive Services Task Force (USPSTF) first recommended low dose computed tomography (LDCT) lung cancer screening. Annual percentage changes: 55-80 (2010-13): 1.9%, P=0.06; 55-80 (2013-18): 3.9%, P<0.001; 45-54 (2010-18): 3.4%, P<0.001; 55-64 (2010-13): 1.3%, P=0.30; 55-64 (2013-18): 4.9%, P=0.001; 65-80 (2010-14): 2.3%, P=0.001; 65-80 (2014-18): 3.8%, P<0.001. “Raw” denotes actual percentage of patients with stage I disease at diagnosis each year. “Model” denotes results of joinpoint regression modeling. An interactive version of this graphic is available at https://public.flourish.studio/visualisation/8864567/

    Journal: The BMJ

    Article Title: Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study

    doi: 10.1136/bmj-2021-069008

    Figure Lengend Snippet: Trends in percentage of patients aged 55-80 and aged 45-54, 55-64, and 65-80 in National Cancer Database with stage I non-small cell lung cancer at diagnosis from 2010 to 2018. Each consecutive annual interval is represented as a point value. Vertical dotted line represents date when United States Preventive Services Task Force (USPSTF) first recommended low dose computed tomography (LDCT) lung cancer screening. Annual percentage changes: 55-80 (2010-13): 1.9%, P=0.06; 55-80 (2013-18): 3.9%, P<0.001; 45-54 (2010-18): 3.4%, P<0.001; 55-64 (2010-13): 1.3%, P=0.30; 55-64 (2013-18): 4.9%, P=0.001; 65-80 (2010-14): 2.3%, P=0.001; 65-80 (2014-18): 3.8%, P<0.001. “Raw” denotes actual percentage of patients with stage I disease at diagnosis each year. “Model” denotes results of joinpoint regression modeling. An interactive version of this graphic is available at https://public.flourish.studio/visualisation/8864567/

    Article Snippet: We used Joinpoint Software Version 4.9.0.0 and Stata/MMP Version 17.0 for PC for statistical analyses.

    Techniques: Biomarker Discovery, Computed Tomography

    Trends in median all cause survival of patients aged 55-80 in National Cancer Database diagnosed as having stage I-IV non-small cell lung cancer from 2010 to 2018. Each consecutive annual interval is represented as a point value. Vertical dotted line represents date when United States Preventive Services Task Force (USPSTF) first recommended low dose computed tomography (LDCT) lung cancer screening. Annual percentage changes: 55-80 (2010-13): 4.1%, P=0.06; 55-80 (2013-17): 11.9%, P=0.001. “Raw” denotes actual median all cause survival of patients each year. “Model” denotes results of joinpoint regression modeling. An interactive version of this graphic is available at https://public.flourish.studio/visualisation/8876375/

    Journal: The BMJ

    Article Title: Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study

    doi: 10.1136/bmj-2021-069008

    Figure Lengend Snippet: Trends in median all cause survival of patients aged 55-80 in National Cancer Database diagnosed as having stage I-IV non-small cell lung cancer from 2010 to 2018. Each consecutive annual interval is represented as a point value. Vertical dotted line represents date when United States Preventive Services Task Force (USPSTF) first recommended low dose computed tomography (LDCT) lung cancer screening. Annual percentage changes: 55-80 (2010-13): 4.1%, P=0.06; 55-80 (2013-17): 11.9%, P=0.001. “Raw” denotes actual median all cause survival of patients each year. “Model” denotes results of joinpoint regression modeling. An interactive version of this graphic is available at https://public.flourish.studio/visualisation/8876375/

    Article Snippet: We used Joinpoint Software Version 4.9.0.0 and Stata/MMP Version 17.0 for PC for statistical analyses.

    Techniques: Computed Tomography

    Trends from 2010 to 2018 in percentage of stage I non-small cell lung cancer diagnosed (top) and in median all cause survival (bottom) among patients aged 55-79 in Surveillance Epidemiology End Results Program database living in high screening (US states where lung cancer screening rate is above national average lung cancer screening rate in 2018) and low screening (US states where lung cancer screening rate is below national average lung cancer screening rate in 2018) states. Each consecutive annual interval is represented as a point value. Vertical dotted line represents date when United States Preventive Services Task Force (USPSTF) first recommended low dose computed tomography (LDCT) lung cancer screening. Annual percentage changes were as follows. Low screen, percentage diagnosed 2010-12: 1.0%, P=0.40; 2012-18: 3.7%, P<0.001. High screen, percentage diagnosed 2010-13: 0.9%, P=0.41; 2013-18: 5.4%, P<0.001. Low screen, median survival 2010-17: 5.9%, P<0.001. High screen, median survival 2010-14: 2.2%, P=0.39; 2014-17: 13.4%, P=0.04. “Raw” denotes actual percentage of patients with stage I disease at diagnosis and median all cause survival of patients each year. “Model” denotes results of joinpoint regression modeling. An interactive version of this graphic is available at https://public.flourish.studio/visualisation/8876566/

    Journal: The BMJ

    Article Title: Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study

    doi: 10.1136/bmj-2021-069008

    Figure Lengend Snippet: Trends from 2010 to 2018 in percentage of stage I non-small cell lung cancer diagnosed (top) and in median all cause survival (bottom) among patients aged 55-79 in Surveillance Epidemiology End Results Program database living in high screening (US states where lung cancer screening rate is above national average lung cancer screening rate in 2018) and low screening (US states where lung cancer screening rate is below national average lung cancer screening rate in 2018) states. Each consecutive annual interval is represented as a point value. Vertical dotted line represents date when United States Preventive Services Task Force (USPSTF) first recommended low dose computed tomography (LDCT) lung cancer screening. Annual percentage changes were as follows. Low screen, percentage diagnosed 2010-12: 1.0%, P=0.40; 2012-18: 3.7%, P<0.001. High screen, percentage diagnosed 2010-13: 0.9%, P=0.41; 2013-18: 5.4%, P<0.001. Low screen, median survival 2010-17: 5.9%, P<0.001. High screen, median survival 2010-14: 2.2%, P=0.39; 2014-17: 13.4%, P=0.04. “Raw” denotes actual percentage of patients with stage I disease at diagnosis and median all cause survival of patients each year. “Model” denotes results of joinpoint regression modeling. An interactive version of this graphic is available at https://public.flourish.studio/visualisation/8876566/

    Article Snippet: We used Joinpoint Software Version 4.9.0.0 and Stata/MMP Version 17.0 for PC for statistical analyses.

    Techniques: Computed Tomography, Biomarker Discovery

    Trends in number of lung cancer cases diagnosed in US among people aged 55-79 from 2010 to 2018 by stage group. Incident lung cancer cases in Surveillance Epidemiology End Results (SEER) Program database were multiplied by 3.57 to obtain total number of lung cancers diagnosed among people aged 55-79 in US by stage group. This estimate assumes that 28% sample of US population included in SEER Program database is unbiased and representative. Each consecutive annual interval is represented as a point value. Vertical dotted line represents date when United States Preventive Services Task Force (USPSTF) first recommended low dose computed tomography (LDCT) lung cancer screening. Annual percentage changes: stage 1 (2010-13): 3.4%, P=0.03; stage 1 (2013-18): 7.4%, P<0.001; stage 2 (2010-18): 3.6%, P=0.009; stage 3 (2010-15): 0.4%, P=0.65; stage 3 (2015-18): –6.6%, P=0.03; stage 4 (2010-16): 1.8%, P=0.01; stage 4 (2016-18): –4.4%, P=0.11. “Raw” denotes actual number of lung cancers by stage group diagnosed each year. “Model” denotes results of joinpoint regression modeling. An interactive version of this graphic is available at https://public.flourish.studio/visualisation/8876872/

    Journal: The BMJ

    Article Title: Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study

    doi: 10.1136/bmj-2021-069008

    Figure Lengend Snippet: Trends in number of lung cancer cases diagnosed in US among people aged 55-79 from 2010 to 2018 by stage group. Incident lung cancer cases in Surveillance Epidemiology End Results (SEER) Program database were multiplied by 3.57 to obtain total number of lung cancers diagnosed among people aged 55-79 in US by stage group. This estimate assumes that 28% sample of US population included in SEER Program database is unbiased and representative. Each consecutive annual interval is represented as a point value. Vertical dotted line represents date when United States Preventive Services Task Force (USPSTF) first recommended low dose computed tomography (LDCT) lung cancer screening. Annual percentage changes: stage 1 (2010-13): 3.4%, P=0.03; stage 1 (2013-18): 7.4%, P<0.001; stage 2 (2010-18): 3.6%, P=0.009; stage 3 (2010-15): 0.4%, P=0.65; stage 3 (2015-18): –6.6%, P=0.03; stage 4 (2010-16): 1.8%, P=0.01; stage 4 (2016-18): –4.4%, P=0.11. “Raw” denotes actual number of lung cancers by stage group diagnosed each year. “Model” denotes results of joinpoint regression modeling. An interactive version of this graphic is available at https://public.flourish.studio/visualisation/8876872/

    Article Snippet: We used Joinpoint Software Version 4.9.0.0 and Stata/MMP Version 17.0 for PC for statistical analyses.

    Techniques: Computed Tomography